A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer  by Chia, Kee Ming et al.
A Feedback Loop between
Androgen Receptor and
ERK Signaling in Estrogen
Receptor–Negative
Breast Cancer1
Kee Ming Chia*, Ji Liu*, Glenn D. Francis†
and Ali Naderi*
*University of Queensland Diamantina Institute, Princess
Alexandra Hospital, Brisbane, Queensland, Australia;
†Pathology Queensland, Princess Alexandra Hospital,
Brisbane, Queensland, Australia
Abstract
Estrogen receptor (ER)–negative breast cancer is heterogeneous, and the biology of this disease has remained poorly
understood. Molecular apocrine is a subtype of ER-negative breast cancer that is characterized by the overexpression
of steroid-response genes such as AR and a high rate of ErbB2 amplification. In this study, we have identified a posi-
tive feedback loop between the AR and extracellular signal–regulated kinase (ERK) signaling pathways in molecular
apocrine breast cancer. In this process, AR regulates ERK phosphorylation and kinase activity. In addition, AR inhibi-
tion results in the down-regulation of ERK target proteins phospho-RSK1, phospho–Elk-1, and c-Fos using an in vivo
molecular apocrine model. Furthermore, we show that AR-mediated induction of ERK requires ErbB2, and AR activity,
in turn, regulates ErbB2 expression as an AR target gene. These findings suggest that ErbB2 is an upstream connector
between the AR and ERK signaling pathways. Another feature of this feedback loop is an ERK-mediated regulation of
AR. In this respect, the inhibition of ERK phosphorylation reduces AR expression and CREB1-mediated transcriptional
regulation of AR acts as a downstream connector between the AR and ERK signaling pathways in molecular apocrine
cells. Finally, we demonstrate that AR-positive staining is associated with the overexpression of ERK signaling targets
phospho–Elk-1 and c-Fos in ER-negative breast tumors, which further supports a cross-regulation between the AR
and ERK signaling pathways in molecular apocrine subtype. This study demonstrates an AR-ERK feedback loop in
ER-negative breast cancer with significant biologic and therapeutic implications in this disease.
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Introduction
Estrogen receptor–negative (ER−) breast cancer constitutes around
30% of all cases and commonly affects a younger patient population
than ER+ disease [1]. In contrast to ER+ breast cancer, where the
estrogen receptor signaling has a critical biologic and therapeutic role,
ER− breast cancer is heterogeneous, and there is limited knowledge
available regarding the pathophysiology of this disease.
Using expression microarray profiling, ER− breast cancer can be
classified into molecular apocrine and basal subtypes [2]. Molecular
apocrine subtype is characterized by a steroid-response gene signature
that includes androgen receptor (AR) and a high frequency of ErbB2
overexpression [2–4]. Subsequent studies have demonstrated that AR
is expressed in approximately 50% of ER− breast cancers and more
than 50% of these cases also have ErbB2 overexpression [5–8]. Fur-
thermore, it has recently been suggested that a loss of PTEN at early
stages of tumorigenesis predisposes to the formation of breast tumors
with molecular apocrine features [9].
The AR signaling pathway has a significant role in the proliferation
and survival of molecular apocrine breast cancer cells [4,5,10]. Nota-
bly, there is a therapeutic value in the inhibition of AR using in vitro
and in vivo models of molecular apocrine cells [4,5,10]. In this respect,
there is currently an ongoing clinical trial evaluating the efficacy of AR
inhibition in patients with AR+/ER− breast cancer (ClinicalTrials.gov
identifier: NCT00468715). Moreover, we have identified a cross talk
between the AR and ErbB2 signaling in molecular apocrine cells that
modulates cell proliferation and expression of steroid-response genes
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[5]. In addition, a recent meta-analysis study has further confirmed
this cross talk and demonstrated that there are interactions between
the AR pathway, epidermal growth factor receptor trafficking signals,
and ErbB2 in molecular apocrine breast cancer [11].
Although the mechanism of cross talk between AR and ErbB2 is
not understood, we have found that extracellular signal–regulated
kinase (ERK) phosphorylation is modulated in this process [5]. ERK
is a critical downstream target of epidermal growth factor receptor–
ErbB2 and activates signaling proteins such as 90-kDa ribosomal S6
kinases (RSK) and transcription factor Elk-1 that are versatile mediators
of ERK signal transduction [12–14]. Moreover, we have recently dem-
onstrated that the combination of AR inhibition and persistent ERK
phosphorylation using flutamide and a Cdc25A phosphatase inhibitor
PM-20, respectively result in a synergistic reduction of cell growth in
molecular apocrine cells [10]. Importantly, this effect is associated with
a synergistic reduction of RSK and Elk-1 phosphorylation and down-
regulation of steroid-response genes [10]. Together, these findings raise
the possibility of an interaction between the AR and ERK signaling
pathways in molecular apocrine breast cancer. Interestingly, a cross talk
between AR and ERK has been reported in prostate cancer and con-
tributes to the progression of this disease [15]. Study of a possible
interaction between the AR and ERK signaling pathways and iden-
tification of a molecular mechanism for this process would signifi-
cantly advance our understanding of molecular apocrine breast cancer
and potentially lead to the development of novel targeted therapies in
this disease.
In this study, we investigate a cross-regulation between the AR and
ERK signaling using in vitro and in vivomodels. Our results suggest a
feedback loop between the AR and ERK signaling pathways involv-
ing ErbB2 and CREB1 in molecular apocrine breast cancer.
Materials and Methods
Cell Culture and Treatments
Breast cancer cell lines MDA-MB-453, HCC-1954, and MCF-7
were obtained from American Type Culture Collection (Manassas,
VA). All the culture media were obtained from Invitrogen (Melbourne,
Australia). MDA-MB-453 and HCC-1954 cell lines were cultured in
L15 media, 10% FBS and RPMI 1640 media, 10% FBS, respectively.
MCF-7 cell line was cultured in Dulbecco modified Eagle medium/
F12 media, 10% FBS. The following treatments were applied for the
cell culture experiments: 1) AR inhibitor, flutamide (Sigma-Aldrich,
Sydney, Australia) at 25 to 80 μM concentrations; 2) 5α-androstan-
17β-ol-3-one (dihydrotestosterone [DHT]; Sigma-Aldrich) at 100 nM
concentration [16]; 3) MEK inhibitor CI-1040 (PD184352; Selleck
Chemicals, Houston, TX) at 2 to 10 μM concentrations; and 4) ErbB2
inhibitor, AG825 (Calbiochem, Melbourne, Australia) at 10 μM con-
centration. Treatments with the inhibitors were performed in medium
containing FBS. DHT treatment was carried out in phenol red–free
Dulbecco modified Eagle medium (Invitrogen) with 10% charcoal/
dextran–treated serum (HyClone, Melbourne, Australia), and cell lines
were cultured in this medium for 48 hours before DHT treatment.
Western Blot Analysis
Rabbit monoclonal ERK1/2 antibody, rabbit monoclonal phospho-
ERK1/2 (Thr202/Tyr204) antibody, rabbit polyclonal AR antibody,
and rabbit polyclonal ErbB2 antibody were obtained from Cell Signal-
ing (Danvers, MA). Western blots were carried out at 1:1000 dilution
of each primary antibody using 20 and 30 μg of cell lysates for the total
and phospho-proteins, respectively. Protein concentrations from the
cell isolates were measured using the BCA Protein Assay Kit (Thermo
Scientific, Melbourne, Australia). Rabbit polyclonalα-tubulin antibody
(Abcam, Cambridge, UK) was used as the loading control. Analysis of
band densities was performed using Bio-Profil Densitometer Software
(Vilber Lourmat, Eberhardzell, Germany). All fold changes in band
densities were measured relative to the control groups. Western blots
were done in two biologic replicates, and the average fold change was
shown for each set of experiments.
AR Knockdown in Cell Lines
AR knockdown (KD) was carried out using the following small
interfering (siRNA) oligos (duplex; Sigma-Genosys, Sydney, Australia):
D1 5′CCAUCUUUCUGAAUGUCCU and D2 5′AGGACAUU-
CAGAAAGAUGG as described before [17]. Transfection of siRNA
oligos using Lipofectamine RNAiMAX (Invitrogen) was carried out
by reverse transfection method as instructed by the manufacturer.
The final siRNA duplex concentration was 10 nM for the knock-
down experiments. Cells transfected with siRNA Universal Negative
Control no. 1 (Sigma-Genosys) were used as controls. In all ex-
periments, the effects of AR-KD were assessed 72 hours after the
siRNA transfections. All siRNA silencing experiments were performed
in four replicates.
Real-time Polymerase Chain Reaction Analysis
Total RNA extraction was performed as described before [18].
Real-time polymerase chain reaction (RT-PCR) to assess the expres-
sion level of AR (assay ID, Hs00907244_m1) was carried out using
TaqMan Gene Expression Assays (Applied Biosystems, Melbourne,
Australia) as instructed by the manufacturer. Housekeeping genes
HPRT1 and RPLP0 (Applied Biosystems) were used as controls. Rela-
tive gene expression = gene expression in the treated group/average gene
expression in the control group. All experiments were performed in four
biologic replicates.
ERK Kinase Assay
ERK kinase assay was carried out using MAP Kinase/ERK Immuno-
precipitation Kinase Assay Kit (Millipore, Sydney, Australia) following
the manufacturer’s instructions. HCC-1954 and MDA-MB-453 cells
were grown in full medium to 60% confluence in 150-mm tissue culture
dishes. Next, DHT treatment was carried out for 3 and 12 hours in
MDA-MB-453 and HCC-1954 lines, respectively. Immunoprecipita-
tion was carried out using anti–MAP kinase–ERK1/2, agarose conjugate
(Millipore), and immunoblot analysis was performed with 1 μg/ml of
anti–phospho myelin basic protein as instructed by the manufacturer
(Millipore). Vehicle-only–treated cells were used as a control.
Luciferase Reporter Assays
Full-length complementary DNA (cDNA) clones for CREB1 and
c-Fos were obtained from Open Biosystems (Thermo Scientific). The
clones were validated by restriction digestion/sequencing and then
subcloned in a pcDNA3.1 vector (Invitrogen) to generate expression
constructs. Full-length cDNA clone for Elk-1 in a pReciever expression
vector was obtained from GeneCopoeia (Rockville, MD). Furthermore,
the sequence of the 1.5-kb promoter region of AR was obtained using
the Ensembl Genome Browser and PCR-generated using the following
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primers: forward GCGCGGTACCCACAATGCCACGAGGCC-
CGA and reverse GCGCGAGCTCACTTGCGGGAGCAACCA-
CGC. Subsequently, AR promoter was cloned in a pGL3 luciferase
reporter vector (Promega, Sydney, Australia) and validated by restriction
digestion/sequencing.
To carry out the reporter assays, MCF-7 cells were cotransfected
with the AR reporter vector and each of the transcription factors using
ExGen 500 reagent (Fermentas Life Sciences, St Leon-Rot, Germany).
The Renilla pRL-TK vector (Promega) was used as an internal control
reporter. Cotransfection with AR reporter vector and an empty pcDNA
vector was used as a control. Forty-eight hours after the transfections,
reporter activities were measured using Dual-Glo Luciferase Assay
System (Promega) in an Orion II Microplate Luminometer (Berthold
Detection Systems, Pforzheim, Germany). The response ratios for tran-
scription factors and control were measured relative to the internal con-
trol reporter (relative response ratio). All reporter assays were carried out
in four biologic replicates.
Bioinformatics Analysis
The sequence of the 1.5-kb promoter regions of ErbB2 and AR were
obtained using the Ensembl Genome Browser (http://www.ensembl.
org/index.html). Identification of putative transcription factor binding
sites in these promoter regions was carried out using PATCH public 1.0
software (http://www.gene-regulation.com/cgi-bin/pub/programs/
patch/bin/patch.cgi) and TRANSFAC 6.0 database (http://www.
gene-regulation.com/cgi-bin/pub/databases/transpath/search.cgi). Data
were then examined for the number and location of AR putative bind-
ing sites on ErbB2 promoter and that of CREB1, c-Fos, and Elk-1 tran-
scription factors on AR promoter.
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed in
MDA-MB-453 cell line using ChIP Assay Kit (USB Corporation,
Cleveland,OH) as instructed by themanufacturer [19]. ChIP-grade rab-
bit monoclonal CREB1 (ChIPAb+ CREB Kit; Millipore) and rabbit
polyclonal AR (Millipore) antibodies were applied for these assays at
1:100 dilutions. Two sets of primers for ErbB2 promoter and three sets
of primers for AR promoter were used for the end point RT-PCR am-
plification using SYBR green method (Applied Biosystems). ErbB2
promoter primers included the following: Primer set 1, forward primer
GCGCGAAGAGAGGGAGAAAGTGAA (start −345) and reverse
primer CCAACAAGTCTGGGAGTGGCAACT (start −291); and
Primer set 2, forward primerGGATGCAAGCTCCCCAGGAAAGTT
(start −549) and reverse primer CCCTAAATGCAGAGGCTGGT-
GACT (start −421). AR promoter primers included the following:
Primer set 1, forward primer TGCCCTTTCCTCTTCGGTGAAGT
(start −382) and reverse primer ACCAGGCACTTTCCTTGCTTCCT
(start −312); Primer set 2, forward primer GGAAAGCAGGAGCTAT-
TCAGGAAGCA (start −842) and reverse primer CCTGCCTAGTG-
GCTTTGGAGAAACAA (start −733); and Primer set 3, forward
primer GCAAGCGGCTGCATACAAAGCAAA (start −1375) and re-
verse primer TGCCATGTACACATAGGCGCTCAAT (start −1304).
Amplification of input chromatin before immunoprecipitation at a dilu-
tion of 1:50 was used as a positive control. ChIP using negative control
supernatant (ChIPAb+ CREB Kit; Millipore) and nonspecific antibody
(rabbit IgG) served as negative controls for AR and ErbB2 promoter
ChIP assays, respectively. The assays were carried out in three repli-
cates, and copy number changes were calculated as −Log2 value for each
experimental set.
Tumor Xenograft Studies
Animal ethics approval was obtained for the project, and mice were
maintained in accordance with the Institutional Animal Care guide-
lines. Six-week-old female nonobese diabetic/severe combined im-
munodeficient mice were purchased from Animal Resource Center
(WA, Australia). The method for generating the tumors in mice was
performed as previously published [10,20]. A total of 5 × 106 MDA-
MB-453 cells were injected into the flank of each mouse to generate
the xenograft tumors [10]. Treatments were initiated 7 days after the
cell injections. A total of 16 mice were studied in the following groups
(four mice for each treatment or control group):
A) Flutamide experiments: 1) treatment with 25 mg/60-day slow-
release flutamide pellets (Innovative Research of America, Sarasota,
FL) and 2) control group with placebo pellets (Innovative Re-
search of America). The pellets were implanted subcutaneously
through a 1-cm incision on the flank of anesthetized mice.
B) MEK inhibitor experiments: 1) treatment with daily oral gavage
of MEK inhibitor PD0325901 (Selleck Chemicals) at 15 mg/kg
per day as described before [21]. PD0325901 was prepared at
a stock concentration of 50 mg/ml in DMSO (Sigma-Aldrich)
and made up to the daily working concentration in 0.05%
methylcellulose/0.02% Tween-80 (Sigma-Aldrich). 2) Control
group with daily gavage of an equal volume of DMSO to that of
the treatment group in the same carrier solution.
Xenograft tumors were harvested 28 days after the start of treatment
in each group. The harvested tumors were fixed in formalin and em-
bedded in paraffin for immunohistochemistry (IHC) staining.
Immunohistochemistry
IHC staining was performed using EnVision+ System-HRP (AEC;
DakoCytomation, Botany, Australia) following the manufacturer’s in-
struction. Antigen retrieval was carried out using Target Retrieval Solution
(DakoCytomation). The following primary antibodies were obtained
from Abcam: rabbit polyclonal phospho–Elk-1 (S383), rabbit mono-
clonal phospho-RSK1 (T359 + S363), rabbit polyclonal c-Fos, and
rabbit polyclonal AR. Primary antibody incubations were carried out
at 1:50 dilution for phospho–Elk-1 and at 1:100 dilutions for the other
antibodies. Slides were counterstainedwith hematoxylin (Sigma-Aldrich)
and mounted using Glycergel Mounting Medium (DakoCytomation).
For IHC scoring, slides were examined using a light microscope (Nikon
Instruments, Inc, Tokyo, Japan). A total of 1000 cells per slide were
counted at 60× magnification to assess the percentage of cells showing
positive staining for each antibody. Scoring was carried out separately by
two investigators, and the average scores were used for the final analysis.
Primary Breast Tumors
The institutional research ethics committee approved this study and
informed consent was obtained from each patient for the use of tissue
samples. A total of 24 paraffin-embedded ER− breast tumor samples
were obtained from the Princess Alexandra Hospital tissue bank. IHC
staining for AR, phospho–Elk-1, and c-Fos was carried out as de-
scribed above. For downstream analysis, tumors were classified into
two groups based on their AR staining pattern: 1) AR+ group with
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20% of cells or more showing positive AR staining and 2) AR− group
with less than 20% of cells stained for AR.
Statistical Analysis
Biostatistical analysis was done using SPSS version 17.0 (SPSS, Inc,
Chicago, IL). Mann-WhitneyU test was applied for the comparison of
nonparametric data.
Results
AR Regulates the Phosphorylation of ERK
To investigate a possible AR regulation of ERK signaling, we first
examined the effect of AR activation using DHTon the phosphoryla-
tion of ERK in molecular apocrine cells. MDA-MB-453 and HCC-
1954 cell lines were treatedwith 100 nMofDHTat various time points,
and the expression of total and phospho-ERK proteins was assessed
using Western blot analysis. In MDA-MB-453 cells, we observed a
rapid induction of phospho-ERK after DHT treatment, which lasted
for 1 hour with a peak phospho-ERK/total-ERK ratio of 1.6-fold at
30 minutes compared with the untreated control (Figure 1A). Further-
more, in HCC-1954 cells, there was an induction of phospho-ERK at
30 minutes, which persisted for 12 hours after DHT treatment with a
peak phospho-ERK/total-ERK ratio of 3.8-fold at 12 hours compared
with the untreated control (Figure 1B). Moreover, there was no sig-
nificant change in the amount of total-ERK after DHT treatments in
these cell lines (Figure 1, A and B).
We next investigated the effect of AR inhibition using flutamide on
ERK phosphorylation in MDA-MB-453 and HCC-1954 cell lines.
Flutamide treatments were carried out for 48 hours before harvesting
cell lysates for Western blot analysis. In addition, we examined a pos-
sible synergy between flutamide and MEK inhibitor CI-1040 in the
reduction of ERK phosphorylation in these cell lines. CI-1040 treat-
ments were carried out for 24 hours before harvesting cell lysates,
and we tested the effect of various concentrations of CI-1040 on the
phosphorylation of ERK.We observed that CI-1040 at 10-μMconcen-
tration almost completely inhibited ERK phosphorylation in both cell
lines (Figure 1C). However, CI-1040 at 2 μM concentration resulted
in a partial reduction of ERK phosphorylation in cell lines to around
0.21- to 0.26-fold compared with the controls (Figure 1, D and E).
Notably, in MDA-MB-453 cells, flutamide at 40 μM completely
inhibited ERK phosphorylation, and the addition of flutamide at
25-μM concentration to CI-1040 at 2 μM resulted in a synergistic
inhibition of ERK phosphorylation to undetectable levels (Figure 1,
D and E ). Moreover, a similar pattern of response was observed in
the HCC-1954 cell line, in which flutamide at 60- and 80-μM con-
centrations resulted in a dose-dependent reduction of ERK phosphor-
ylation to 0.58- and 0.29-fold compared with the controls (Figure 1F).
Furthermore, in HCC-1954 cells, the addition of flutamide at 40-μM
concentration to CI-1040 at 2 μM resulted in a synergistic inhibition
of ERK phosphorylation to undetectable levels (Figure 1D). As ob-
served with DHT experiments, we did not find any changes in the
total ERK levels after flutamide treatment in molecular apocrine cells
(Figure 1, D–F).
We further studied the effect of AR down-regulation on the phos-
phorylation of ERK using RNA interference. AR-KD was carried out
using a siRNA duplex as described in the Materials and Methods sec-
tion, and the efficiency of knockdown was assessed by RT-PCR and
Western blot analysis. We observed an approximately 85% reduction
of AR transcript and protein levels after AR-KD (Figure 2, A and B).
It is notable that MDA-MB-453 cells showed a markedly higher base-
line level of AR compared with HCC-1954 cells (Figure 2B). Further-
more, AR down-regulation resulted in the reduction of phospho-ERK/
total-ERK ratio to 0.57-fold in MDA-MB-453 and to 0.9-fold in
HCC-1954 cells (Figure 2C).
These findings suggest that AR activity is both necessary and suf-
ficient for the phosphorylation of ERK in molecular apocrine cells.
In addition, MDA-MB-453 cells show a higher degree of sensitivity
to the effect of AR inhibition and knockdown in reducing ERK
phosphorylation compared with HCC-1954 cells.
AR Induces ERK Kinase Activity
Because AR activation induces the phosphorylation of ERK, we
next asked whether a similar effect can be observed for ERK kinase
activity. MDA-MB-453 and HCC-1954 cell lines were treated with
DHT at 100 nM concentration for 3 and 12 hours, respectively, and
ERK activity was measured using immunoprecipitation kinase assay as
described in the Materials and Methods section. We observed a low
baseline ERK kinase activity in these cell lines (Figure 2D). Impor-
tantly, in both cell lines, there was a marked induction of ERK activity
by three-fold compared with the controls after DHT treatment (Fig-
ure 2D). These findings suggest that AR activates ERK kinase in
molecular apocrine cells.
ErbB2 Is Required for AR-Induced ERK Phosphorylation
It is known that ErbB2 has a critical role in the activation of ERK
signaling [22]. In addition, we have previously shown a functional cross
talk between the AR and ErbB2 pathways in molecular apocrine
cells [5]. Therefore, we next investigated a possible role for ErbB2 in
AR-mediated induction of ERK. MDA-MB-453 and HCC-1954 cell
lines were treated with a selective ErbB2 inhibitor, AG825, at 10 μM
for 24 hours before DHT treatment. DHT treatments were carried out
for 1 hour and 12 hours in MDA-MB-453 and HCC-1954, respec-
tively, corresponding to the peak DHT response in each cell line as
shown before (Figure 1, A and B). Cell lines treated with AG825 alone
were used as controls, and the expression of total and phospho-ERK
proteins was assessed using Western blot analysis. It is notable that
we did not observe any change in the level of ERK phosphorylation
after DHT treatment in AG825-pretreated cell lines (Figure 3A). This
finding suggests that ErbB2 activity is required for AR-mediated in-
duction of ERK phosphorylation in molecular apocrine cells.
ErbB2 Is a Transcriptional Target of AR
Because ErbB2 activity is necessary for AR induction of ERK, we
next examined a possible AR regulation of ErbB2 in molecular apocrine
cells. In this respect, we first assessed the effect of AR activation using
DHTon ErbB2 expression. MDA-MB-453 and HCC-1954 cell lines
were treated with DHT for 1 hour and 12 hours, respectively, and
the expression of ErbB2 was assessed using Western blot analysis. We
observed that there was an increase in ErbB2 expression by 2.8- and
1.8-fold in MDA-MB-453 and HCC-1954 cells, respectively, after
DHT treatment compared with the untreated controls (Figure 3B).
We next studied the effect of AR inhibition using flutamide on
ErbB2 expression. MDA-MB-453 and HCC-1954 cell lines were
treated with flutamide for 48 hours at 40- and 80-μM concentrations,
respectively. There was a marked reduction of ErbB2 protein level to
0.2-fold in MDA-MB-453 and to 0.55-fold in HCC-1954 after fluta-
mide treatments compared with the untreated controls (Figure 3C ).
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Furthermore, we assessed the effect of AR-KD on ErbB2 protein level
and found that ErbB2 level was reduced to 0.33-fold inMDA-MB-453
and to 0.9-fold in HCC-1954 cells after AR-KD compared with con-
trol siRNA-transfected cell lines (Figure 3D). These findings suggest
that AR activity is necessary and sufficient for ErbB2 expression.
To explain these observations, we first examined the 1.5-kb ErbB2
promoter region using bioinformatics programs and identified two AR
putative binding sites at −556 and −577 bp. We next carried out ChIP
assay to test AR binding to the ErbB2 promoter. Two sets of primers
for ErbB2 promoter were used for the end point RT-PCR amplification
Figure 1. AR regulation of ERK phosphorylation. (A) Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-
453 cells after treatment with 100 nM of DHT at various time points. Fold changes (RR) in band densities were measured relative to the
untreated control (CTL) and RR for phospho-ERK and total ERK were shown for each condition. (B) Western blot analysis to measure the
phosphorylated and total ERK levels in HCC-1954 cells after treatment with DHT as described in (A). (C) Western blot analysis to measure
the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.
(D) Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cells after flutamide (FLU)
and CI-1040 (CI) treatments. CI-1040 and flutamide treatments were carried out at 2- and 40-μM concentrations, respectively. (E) Western
blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 cells. CI-1040 (CI) and flutamide (FLU) treatments were
carried out at 2- and 25-μM concentrations, respectively. (F) Western blot analysis to measure the phosphorylated and total ERK levels in
HCC-1954 cells. Flutamide treatments were performed at 60- and 80-μM concentrations.
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as described in the Materials and Methods section. Amplification of
input chromatin at a dilution of 1:50 served as a positive control (Input)
and ChIP using nonspecific antibody (rabbit IgG) as a negative control.
Copy number changes were calculated as −Log2 value for each experi-
mental set (Figure 3E). Importantly, we observed enrichment for ErbB2
promoter region with AR antibody using each of the two primer sets
(P < .01; Figure 3E ). These findings demonstrate that AR binds to
the ErbB2 promoter, and ErbB2 is an AR target gene.
ERK Regulates AR Expression
We have previously reported a synergistic down-regulation of steroid-
response genes after the combined administration of Cdc25A phospha-
tase inhibitor PM-20 and flutamide that was accompanied with the
down-regulation of ERK target proteins in molecular apocrine cells
[10]. Therefore, we next explored the possibility of an ERK-mediated
regulation of AR expression as an additional mechanism of interaction
between these two pathways. To study this effect, MDA-MB-453 and
HCC-1954 cell lines were treated with CI-1040 at 10-μM concen-
tration for 24 hours, and vehicle (DMSO)-treated cells were used as
controls. We then assessed AR expression using RT-PCR and ob-
served a significant reduction of AR transcript level after MEK inhi-
bition to 0.2- and 0.6-fold in MDA-MB-453 and HCC-1954 cells,
respectively, compared with the controls (P < .01; Figure 4A). These
findings suggest that ERK signaling regulates AR expression in molec-
ular apocrine cells.
To explain the underlyingmechanism for our findings, we investigated
the effects of well-characterized ERK signaling transcription factors
CREB1, Elk-1, and c-Fos on AR transcription [23–27]. Examination
of the 1.5-kb AR promoter region identified several putative binding
sites for these transcription factors (Figure 4B). We subsequently used
luciferase reporter assays to examine the effects of these predicted tran-
scription factors on the regulation of AR promoter. Because of a high
degree of transfectability, MCF-7 cells were used for the reporter assay
experiments [19]. MCF-7 cells were cotransfected with the AR reporter
vector and each of the CREB1, Elk-1, and c-Fos expression constructs.
Cotransfection with the AR reporter vector and an empty pcDNAvector
was used as a control. Forty-eight hours after the transfections, reporter
activities were measured, and relative response ratios were calculated as
Figure 2. AR knockdown effect on ERK phosphorylation and DHT induction of ERK kinase activity. (A) RT-PCR to demonstrate AR knock-
down (KD) efficiencies after AR-siRNA transfections in MDA-MB-453 (MDA) and HCC-1954 (HCC) cells. AR expression after knockdown
was assessed relative to nontargeting siRNA control (CTL), and fold change is shown for each cell line. Error bars, ±2 SEMs. (B) Western
blot analysis to show AR protein expression after AR-KD in MDA-MB-453 and HCC-1954 cells. Fold changes (RR) in band densities were
measured relative to the control. (C) Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and
HCC-1954 cell lines after AR-KD. (D) ERK kinase activity. ERK kinase assay was carried out using immunoprecipitation kinase assay.
MDA-MB-453 and HCC-1954 cells were treated with DHT at 100-nM concentration for 3 and 12 hours, respectively. Fold changes (RR)
in band densities after DHT treatment were measured relative to the control group.
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described in the Materials and Methods section. We observed a marked
increase in AR reporter activity with CREB1 by approximately 12-fold
(P < .01; Figure 4C). In addition, Elk-1 and c-Fos did not activate the
AR promoter (Figure 4C).
To test the binding of CREB1 to AR promoter we next carried out
ChIP assay. Three sets of primers for AR promoter were used for the
end point RT-PCR amplification. Amplification of input chromatin
at a dilution of 1:50 and negative control supernatant were applied
as positive and negative controls, respectively. Copy number changes
were calculated as −Log2 value for each experimental set (Figure 4D).
Notably, we observed enrichment for the AR promoter region with
CREB1 antibody using each of the three primer sets (P < .01; Fig-
ure 4D). These data demonstrate that AR is a CREB1 target gene.
AR Inhibition Results in the In Vivo Down-regulation of
ERK Target Proteins
We further investigated the AR regulation of ERK signaling using an
in vivo xenograft model of molecular apocrine breast cancer. Xenograft
Figure 3. AR regulation of ErbB2 expression. (A) Western blot analysis to show the effect of ErbB2 inhibition on AR-induced ERK phosphor-
ylation. AG825 (AG) treatment was carried out at 10 μM for 24 hours. DHT treatmentswere performed for 1 hour and 12 hours inMDA-MB-453
andHCC-1954 cells, respectively. Fold changes (RR) in band densitiesweremeasured relative to AG825-treated lines. (B)Western blot analysis
to show the effect of DHT on ErbB2 protein level. DHT treatments were carried out as in (A). Fold changes (RR) in band densities were mea-
sured relative to the untreated controls. (C) Western blot analysis to show the effect of flutamide on ErbB2 protein level. Flutamide (FLU) treat-
ments were carried out for 48 hours at 40- and 80-μM concentrations in MDA-MB-453 and HCC-1954 cell lines, respectively. (D) Western blot
analysis to show the effect of AR knockdown (KD) on ErbB2 protein level in MDA-MB-453 and HCC-1954 lines. Fold changes (RR) in band
densitiesweremeasured relative to nontargeting siRNA control. (E) ChIP assaywith AR antibody. The results of end point RT-PCR amplification
for ChIP assay are shownwith two sets of primers for ErbB2 promoter. Input indicates input at a dilution of 1:50; Neg. CT, nonspecific antibody.
The relative copy number changes to control are shown as −Log2 values. *P < .01 is for AR Ab. versus Neg. CT. Error bars, ±2 SEMs.
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tumors were generated using MDA-MB-453 cells as described in the
Materials and Methods section. A total of four mice were treated with
slow-release flutamide pellets for 28 days, and tumors were then har-
vested for IHC staining. Mice implanted with the placebo pellets were
used as controls. We next carried out IHC staining for the ERK target
proteins phospho–Elk-1, phospho-RSK1, and c-Fos in the harvested
tumors. Subsequently, we determined the percentage of cells stained
with each antibody and compared the results between flutamide-treated
and placebo groups.
We observed that phospho–Elk-1, phospho-RSK1, and c-Fos expres-
sion were markedly lower in flutamide-treated group compared with the
controls (Figure 5). In this respect, there was an approximately 20% stain-
ing for phospho–Elk-1 in flutamide-treated group comparedwith 60% in
the control group (P < .01; Figure 5, A–C). Furthermore, a similar pat-
tern was observed for phospho-RSK1 and c-Fos with an approximately
three-fold lower staining for these proteins in flutamide-treated group
compared with that in the controls (P < .01; Figure 5,A andD–G). These
findings suggest that the inhibition of AR in vivo leads to the down-
regulation of ERK signaling proteins in molecular apocrine tumors.
ERK Inhibition Leads to an In Vivo Reduction of AR Expression
We subsequently evaluated the in vivo effect of ERK signaling in-
hibition on the expression of AR. Xenograft tumors were generated
using MDA-MB-453 cells, and a total of four mice were treated with
daily oral gavage of MEK inhibitor PD0325901 at 15 mg/kg per day
for 28 days. Mice given daily gavage of an equal volume of DMSO/
carrier solution to that of treatment group were used as controls. Xeno-
graft tumors were harvested at the end of treatment period and stained
Figure 4. ERK regulation of AR expression. (A) Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treat-
ment with CI-1040 (MEK Inh) at 10-μM concentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P< .01 is for
CI-1040 versus control. Error bars, ±2 SEMs. (B) Putative transcription factor binding sites for CREB1, Elk-1, and c-Fos in the 1.5-kb promoter
region of AR. P1 (primer set 1), P2 (primer set 2), and P3 (primer set 3) are regions of amplification for ChIP assays. (C) Luciferase reporter
assay. The transcriptional activation of AR promoter by CREB1, Elk-1, and c-Fos expression constructs was assessed using Dual-Luciferase
Assays in MCF-7 cells, and relative response ratios are reported. Cotransfection with the AR reporter vector and an empty pcDNA vector
was used as a control. *Compared with the control group. Error bars, ±2 SEMs. (D) ChIP assay with CREB1 antibody. The results of end
point RT-PCR amplification for ChIP assay are demonstrated with three sets of primers for AR promoter. Input indicates input chromatin at
a dilution of 1:50; Neg. CT, negative control supernatant. The relative copy number changes to control are shown as−Log2 values. *P< .01
is for CREB1 Ab. versus Neg. CT. Error bars, ±2 SEMs.
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Figure 5. In vivo effect of AR inhibition on ERK target proteins. (A) IHC staining for phospho–Elk-1 (p-Elk1), phospho-RSK1 (p-RSK), and c-Fos
in xenograft tumors. The percentage of cells positive for each protein was assessed using IHC and compared between flutamide-treated
(FLU) and control (CTL) groups. *P < .01 is for FLU versus CTL. Error bars, ±2 SEMs. (B) Phospho–Elk-1 (p-Elk1) IHC in a control xenograft
tumor. Magnification, ×60. (C) Phospho–Elk-1 (p-Elk1) IHC in a flutamide-treated xenograft tumor. Magnification, ×60. (D) Phospho-RSK1
(p-RSK) IHC in a control xenograft tumor. Magnification, ×60. (E) Phospho-RSK1 (p-RSK) IHC in a flutamide-treated xenograft tumor. Mag-
nification, ×60. (F) c-Fos IHC in a control xenograft tumor. Magnification, ×60. (G) c-Fos IHC in a flutamide-treated xenograft tumor. Mag-
nification, ×60.
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for phospho-RSK1 and AR using IHC. The percentage of cells stained
with each antibody was compared between MEK inhibitor and con-
trol groups.
We observed an approximately 50% lower phospho-RSK1 staining
in the treatment group compared with the controls, suggesting a suc-
cessful in vivo down-regulation of ERK signaling with MEK inhibi-
tion (P < .01; Figure 6, A–C ). We next evaluated AR expression in
the treatment and control groups. Importantly, the percentage of AR
staining was markedly lower in the treated tumors at 45% compared
with the controls at 90% (P < .01; Figure 6, A and D–E). These data
demonstrate that there is an in vivo reduction in AR expression after the
inhibition of ERK signaling in molecular apocrine tumors.
AR+/ER− Primary Breast Tumors Have High Expression of
phospho–Elk-1 and c-Fos
To further study our in vitro and in vivo results, we evaluated a cohort
of ER− primary breast tumors for a possible association between the
expression of AR and ERK target proteins. We first carried out IHC
staining for AR in a total of 24 ER− breast tumors and classified these
tumors into AR+ and AR− subgroups as described in the Materials
and Methods section. A total of 12 samples (50% of tumors) showed
AR+ staining in this cohort. We next carried out IHC staining for the
ERK target proteins phospho–Elk-1, phospho-RSK1, and c-Fos in
these breast tumors and compared the percentage of positive staining
for each protein between AR+ and AR− samples.
Figure 6. In vivo effect of MEK inhibition on AR expression. (A) IHC staining for phospho-RSK1 (p-RSK) and AR in xenograft tumors. The
percentage of cells positive for each protein was assessed using IHC and compared between MEK inhibitor–treated (PD) and control (CTL)
groups. *P< .01 is for PD versusCTL. Error bars, ±2 SEMs. (B) Phospho-RSK1 (p-RSK) IHC in a control xenograft tumor. Magnification, ×60.
(C) Phospho-RSK1 (p-RSK) IHC in a MEK inhibitor–treated xenograft tumor. Magnification, ×60. (D) AR IHC in a control xenograft tumor.
Magnification, ×60. (E) AR IHC in a MEK inhibitor–treated xenograft tumor. Magnification, ×60.
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It is notable that AR+ breast tumors showed a significantly higher
expression of phospho–Elk-1 (63% ± 4%) compared with AR− breast
tumors (48% ± 5%, P < .03; Figure 7, A–C ). Furthermore, c-Fos ex-
pression was significantly higher in AR+ (48% ± 3%) compared with
that in AR− samples (34% ± 3%, P < .03; Figure 7, A andD–E). How-
ever, the difference between phospho-RSK1 staining did not reach
statistical significance (Figure 7A). These findings indicate that AR+
staining is associated with a relative overexpression of ERK target pro-
teins phospho–Elk-1 and c-Fos in ER− breast tumors.
Discussion
ER− breast cancer is heterogeneous, and the biology of this disease has
remained poorly understood. Study of key signaling pathways mediat-
ing the development of ER− breast cancer is a necessary step for the
discovery of targeted therapy strategies in this disease. Previous expres-
sion microarray studies have identified a distinct molecular apocrine
subtype in ER− breast cancer that is characterized by the overexpres-
sion of steroid-response genes such as AR and a high rate of ErbB2 am-
plification [2–4]. We have recently demonstrated a functional cross
Figure 7. IHC in primary breast tumors. (A) IHC staining for phospho–Elk-1 (p-Elk1), c-Fos, and phospho-RSK1 (p-RSK) in ER-negative
(ER−) breast tumors. AR+ group indicates 20% of cells or more showing positive AR staining; AR− group, less than 20% of cells
stained for AR. The percentage of cells with positive staining is demonstrated for each group. *P < .03 is for AR+ versus AR−. Error
bars, ±2 SEMs. (B) Phospho–Elk-1 (p-Elk1) IHC in an AR+ breast tumor. Magnification, ×60. (C) Phospho–Elk-1 (p-Elk1) IHC in an AR−
breast tumor. Magnification, ×60. (D) c-Fos IHC in an AR+ breast tumor. Magnification, ×60. (E) c-Fos IHC in an AR− breast tumor.
Magnification, ×60.
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talk between AR and ErbB2 involving the cross-regulation of steroid-
response genes in this subtype [5]. Furthermore, we observed that ERK
phosphorylation was modulated in the process of this cross talk [5]. In
the present study, we have investigated a feedback loop between AR
and ERK signaling in molecular apocrine breast cancer (Figure 8).
One aspect of this feedback loop involves AR regulation of the ERK
signaling pathway. This is evident by the fact that AR activity is both
necessary and sufficient for the induction of ERK phosphorylation in
molecular apocrine cells (Figures 1 and 2). Furthermore, this stimula-
tory effect of AR is observed at the level of ERK kinase activity. Inter-
estingly, a similar time-dependent AR-mediated induction of ERK has
been reported in prostate cancer models [28,29]. In addition, the effect
of AR inhibition in reducing ERK phosphorylation is reproducible
using different approaches including AR inhibition with flutamide,
synergy between flutamide and a low-dose MEK inhibitor, and AR
knockdown (Figures 1 and 2). Moreover, AR inhibition results in the
down-regulation of ERK signaling targets phospho–Elk-1, phospho-
RSK1, and c-Fos using an in vivo xenograft model of molecular apo-
crine tumors (Figure 5). Taken together, these findings suggest that AR
is a regulator of ERK signaling in molecular apocrine cells (Figure 8).
Our data suggest some variation in sensitivity to the effect of AR
inhibition/down-regulation on ERK phosphorylation across molecular
apocrine cell lines. In this respect, MDA-MB-453 cells are more sen-
sitive to the effect of AR inhibition/down-regulation compared with
HCC-1954 cells, and this corresponds to a higher level of AR expres-
sion inMDA-MB-453 line (Figures 1 and 2). It is notable that the level
of ER expression has been associated with a better response to anti-
estrogen therapy in ER+ breast cancer [30,31]. Future clinical studies
are required to determine whether variation in AR expression levels
can similarly act as a predictive marker for sensitivity to AR inhibition
in molecular apocrine patients.
ErbB2 is a known activator of ERK signaling, and it induces AR trans-
activation through the ERK pathway in prostate cancer [22,32,33]. Fur-
thermore, there is a cross talk between AR and ErbB2 at the functional
and genomics levels in molecular apocrine breast cancer [5,11]. Here,
we have demonstrated that AR-mediated induction of ERK requires
ErbB2. In turn, AR activity is necessary and sufficient for ErbB2 ex-
pression and ErbB2 is an AR target gene (Figure 3). These findings are
supported by our previous report that androgens induce ErbB2 mRNA
expression in molecular apocrine cells [5]. Therefore, the transcriptional
regulation of ErbB2 by AR provides a molecular mechanism for AR
modulation of the ERK signaling pathway. Although there may be ad-
ditional mechanisms contributing to the interaction between AR and
ERK, our data suggest that ErbB2 is a key component of this feedback
loop and an upstream connector between the AR and ERK signaling
pathways (Figure 8). Moreover, a functionally active AR signaling may
contribute to the high prevalence of ErbB2 overexpression in molecular
apocrine cells, which, in turn, can lead to the activation of ERK signaling
in this subtype of breast cancer.
Another aspect of the AR-ERK feedback loop is an ERK-mediated
regulation of AR expression in molecular apocrine cells (Figure 8). In
this process, inhibition of ERK phosphorylation results in the down-
regulation of AR expression using both in vitro and in vivo models
of molecular apocrine breast cancer (Figures 4 and 6). Interestingly,
regulation of AR activity by the ERK signaling pathway has also been
observed in prostate cancer models and may contribute to the progres-
sion of this disease [15,34]. Furthermore, our data suggesting that AR
is a CREB1 target gene provides a mechanism for the observed ERK-
mediated regulation of AR in molecular apocrine cells (Figure 4).
CREB1 is a well-characterized ERK signaling transcription factor
and, as a part of the MEK1/2-ERK1/2-CREB1 pathway, is a mediator
of androgen signaling in prostate cancer [23–25,29]. In this respect,
CREB1 is a downstream target of active ERK through the mediation
of RSK and MSK family of kinases, which, on activation, stimulates
transcription of a variety of genes [24,25,35–37]. Therefore, CREB1-
mediated regulation of AR transcription would act as a downstream
connector between the AR and ERK signaling pathways (Figure 8).
Our findings in ER− breast tumors for an association between AR-
positive staining and overexpression of ERK signaling targets phospho–
Elk-1 and c-Fos further supports a cross-regulation between the AR
and ERK signaling pathways in molecular apocrine breast cancer
(Figure 7). It is notable that c-Fos is also a CREB1 target gene and is
regulated in an androgen-dependent way in prostate cancer models
[25,29]. Therefore, in addition to overexpression of steroid-response
genes [3], there is a relative overexpression of ERK signaling targets in
molecular apocrine breast tumors.
In summary, we have identified a positive feedback loop between
the AR and ERK signaling pathways in molecular apocrine breast can-
cer. In this feedback loop, AR regulates ERK phosphorylation through
the mediation of ErbB2 and, in turn, ERK-CREB1 signaling regulates
the transcription of AR in molecular apocrine cells. The biologic sig-
nificance and a potential for targeted therapy highlight the importance
of this feedback loop in ER− breast cancer.
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